Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

HIF-1α at the intersection of hypoxia, ferroptosis-associated stress, and cell death crosstalk in osteomyelitis

Li J., Yang F., Deng X., Yu Y., Huang X., Yang X.

Narrative Review on Chronic Inflammation, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Cell Dev Biol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41695394
PMCID
PMC12901439
DOI
10.3389/fcell.2026.1672284

Abstract (original English)

Osteomyelitis is a severe inflammatory disease of bone tissue primarily caused by bacterial infections, most commonly Staphylococcus aureus . Its complex pathophysiology creates a unique hypoxic and inflamed microenvironment, which leads to the significant upregulation of the key transcriptional regulator, hypoxia-inducible factor-1α (HIF-1α). HIF-1α plays a pivotal role in disease progression, partly by orchestrating various forms of regulated cell death (RCD). The dysregulation of these RCD pathways, including apoptosis, pyroptosis, and particularly the emerging role of ferroptosis, is critically involved in shaping the fate of bone and immune cells, influencing the inflammatory response, and ultimately driving bone destruction. This review aims to comprehensively explore the regulatory mechanisms of HIF-1α on these RCD modalities, especially ferroptosis, and the intricate crosstalk among them. Moreover, we highlight emerging therapeutic strategies targeting the HIF-1α-RCD axis, offering novel insights into the pathogenesis and potential treatment avenues for this refractory orthopedic inflammatory condition.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research